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the native annulus perimeter is> 8,5 cm. In this context the larger CoreValve available
(31 mm) cannot be use as oversizing prosthesis. To the contrary when an oversizing
valve prostheis can be used acceptable results are achieved. In this setting of pts TAVI
showed no death, and good clinical outcomes that were sustained at 3-y FU.
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Background: The incidence and prognostic impact of late bleeding complications
(LBC) after TAVR are unknown. We sought to identify the incidence, predictors, and
prognostic impact of LBC (30 days) after TAVR.
Methods: Clinical and echocardiographic outcomes of patients who underwent
TAVR within the randomized cohorts and continued access registries in the PART-
NER trial were analyzed after stratifying by the occurrence of LBC. Predictors of LBC
and its association with 30-day to 1-year mortality were assessed.
Results: Among 2,401 patients who underwent TAVR and survived to 30 days, LBC
occurred in 142 (5.9%) at median time of 132 [71, 230] days after the index procedure.
Gastrointestinal (n¼58; 40.8%), neurologic (n¼22; 15.5%), and traumatic falls
(n¼11; 7.8%) were identiﬁed as the most frequent types of LBC. Independent pre-
dictors of major LBC were the presence of atrial ﬁbrillation or ﬂutter (AF) at baseline
or 30 days, the presence of moderate/severe paravalvular leak (PVL) at 30 days, the
presence of low hemoglobin at baseline, and greater left ventricular mass at 30 days.
LBC was identiﬁed as a strong independent predictor of mortality between 30 days
and 1 year (adjusted HR 3.91, 95% CI [2.67, 5.71], p< 0.001). The presence of AF,
especially when LBCs occurred, was associated with a poor prognosis and high rate of
mortality.
Conclusions: LBC after TAVR were frequent and associated with increased mor-
tality. A better-individualized and risk-adjusted antithrombotic therapy after TAVR is
urgently needed in this high-risk population.TCT-757
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Background: Transcatheter aortic valve implantation is the contemporary treatment
of choice for high/prohibitive surgical risk patients with severe aortic stenosis.
Methods: Outcomes of consecutive 275 (61% female) severe aortic stenosis patients,
treated with TAVI and followed up to 3 years (mean 702 days), were analyzed and
reported according to the Valve Academic Research Consortium 2 deﬁnitions. The
primary end point was death from any cause.
Results: This patient group (60% women) was characterized by advanced age (mean
81.76.8), high mean log-EuroScore ¼ 19.112 and STS score ¼ 8.15.
The Medtronic-CoreValve device was utilized in 195(71%) and the Edwards-
Sapien device in 80(29%) of patients. The trans-femoral, trans-axillar, trans-apical,JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Vatrans-aortic and retroperitoneal route were used in 224, 20, 29, 1 and 1 patients;
respectively. Procedural success was 97.1%. One month, 1 year, 2 and 3 years survival
rates were 97%, 91%, 85% and 70%; respectively. Peri-procedural\in-hospital stroke
was diagnosed in 9 (3.2%) patients. Permanent pacemaker was required in 40 (14.5%)
patients: (36 cases in CoreValve and 4 in Sapien valves). Signiﬁcant paravalvular leak
(moderate) was noted in 22 (8%) patients. After the procedure, mean valve gradients
decreased from 51.216 to 8.17 (p< 0.001). Symptomatic improvement was
evident during follow up, having 98% of patients in NYHA-FC I or II.Conclusions: The current report signiﬁes that catheter-based treatment of mostly
elderly patients with severe aortic stenosis is feasible, safe and associated with
satisfactory long-term outcomes.
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Background: Acute kidney injury (AKI) is a serious complication after transcatheter
aortic valve implantation (TAVI) and patients with preexisting renal impairment seem
to be especially prone to AKI. Very few data exist about the impact of invasive
hemodynamics on the occurrence of AKI after TAVI. The objectives oft the study
were (i) to determine the incidence and predictive factors for AKI with emphasis on
invasive hemodynamics, and (ii) to examine short-and longterm outcome of these
patients.
Methods: A total of 540 patients (mean age: 80.27.1, logES: 24.517.9%) un-
dergoing TAVI were included in the study. Patients were divided into three groups
according to their glomerular ﬁltration rate (GFR) before TAVI (A: normal renal
function i.e. GFR  60ml/min; B: impaired renal function i.e. GFR 30-59 ml/min; C:
severe impaired renal function i.e. GFR < 30 ml/min). Renal function and survival
were recorded over 12 months.
Results: Overall 30-day mortality was 10.2 % and 12-month mortality was 21.5%.
Subgroup analysis showed signiﬁcant differences between the groups with regard to
30-day-mortality (A: 5.4%, B: 9.0%, C: 25.0%) and 12-month mortality (A: 15.0%, B:
32.0%, C: 49%). AKI occurred in 30 patients (5.6%), of which the majority were
patients of group B (16 patients). 30-day-mortality of patients with AKI was 53.3%
(16 patients) and 12-month-mortality was 73.3% (22 patients). Systemic arterial
pressures were signiﬁcantly higher before and after TAVI in patients without AKI
compared to patients with AKI, whereas preprocedural and postprocedural pulmonary
and right atrial pressures did not differ between both groups. Predictive factors forlvular disease - Aortic: TAVR B221
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comAKI comprised among others non-transfemoral access, anemia, high EURO Score and
the absence of an increase in cardiac output (CO) after TAVI (AKI vs. non-AKI DCO:
0.28.6% vs. 7.226.5%, p< 0.0001).
Conclusions: Preprocedural renal dysfunction has a prominent impact on mortality
after TAVI. In addition, the occurrence of AKI after TAVI carries an even worse
prognosis. In this regard, the maintenance of a sufﬁcient blood pressure and
an increase of cardiac output after TAVI seem to be protective against renal
impairment.
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Background: Neutrophil gelatinase-associated lipocalin (NGAL) is a novel
biomarker associated with acute kidney injury (AKI) after cardiac procedures. NGAL
allows earlier detection of AKI than serum creatinine (SCr) level but has not been
evaluated post transcatheter aortic valve replacement (TAVR).
Methods: From 6/2012-5/2013, we enrolled 66 patients undergoing TAVR in this
single-center pilot study. Urinary NGAL was measured at baseline, 2, 4, and 12 hours
post op. Demographic, procedural features, and SCr until discharge were measured.
The trend of NGAL post TAVR and the association of increased NGAL with AKI as
per VARC-2 criteria was assessed.
Results: Twenty-two patients (33.3%) developed AKI postoperatively (Stage 1,
63.6%; Stage 2, 22.7%; Stage 3, 13.6%). There was no signiﬁcant difference in
baseline SCr, eGFR, or contrast dye volume between patients who developed AKI and
those who did not but AKI patients had a signiﬁcantly smaller aortic valve area. There
was a signiﬁcantly higher level of NGAL in patients with AKI versus those without
AKI seen at 2, 4 and 12 hours post procedure (Figure), with the peak at 2 hours. After
adjusting for gender, age, diabetes, TAVR type, and BMI; NGAL was signiﬁcantly
predictive of AKI at baseline (OR ¼ 1.019 (95% CI 1.001 – 1.037, p¼0.034) and at
each post op measurement.
Conclusions: NGAL was signiﬁcantly elevated in patients who develop AKI both pre
TAVR and post TAVR as early as 2 hours post procedure in this pilot study. This
biomarker may assist in better determining patients at risk for and earlier detection and
management of this frequent complication.TCT-760
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Background: An association between the acquired von Willebrand syndrome
(aVWS) and valvular aortic stenosis (AVS) has been demonstrated in the past.
While the extend of von Willebrand factor (aVWF) deﬁciency is related to the
severity of AVS, surgical valve replacement (SAVR) can lead to factor recovery.
Prevalence and course of the aVWS in patients treated with TAVR though has not
yet been described comprehensively. Thus, we investigated the prevalence of the
aVWS in patients undergoing TAVR and the impact on the underlying factor
variances.
Methods: 104 consecutive patients (age: 81.0  13.0years; logEUROscore
22.918.5%) underwent TAVR at our institution. Comprehensive hemostaseologic
testing was performed prior to and up to one week after TAVR. Transvalvular he-
modynamics and right heart catheterisation as well as bleeding episodes were recorded
and analyzed with descriptive statistics.
Results: Baseline prevalence of an aVWS was 41% with an average densitometric
high-molecular-weight multimer (HMW-MM) count of 16.63.5%. Pressure gradi-
ents correlated signiﬁcantly with the extent of high-molecular-weight multimere
(HMW-MM) deﬁciency (r¼-0.63 [P< 0.0001]). While in the past it has been shown to
be vice-versa for SAVR, the necessity of blood transfusions was higher in our control-
group1. Following valve implantation, HMW-MM increased proportional to the drop
in mean pressure gradient and normalized within a week in 97% of the patients with
prior aVWS.
Conclusions: We describe a signiﬁcant prevalence of aVWS in patients undergoing
TAVR. Since severe factor deﬁciency can lead to signiﬁcant bleeding during SAVR,
TAVR should be taken into consideration as a ﬁrst line treatment for patients with
AVS and concomitant aVWS.
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Background: Balloon aortic valvuloplasty (BAV) has traditionally been part of the
transcatheter aortic valve implantation (TAVI) procedure using balloon expandable
valves. However, the beneﬁt of this is unknown. We aimed to evaluate procedural
success and safety in patients who underwent TAVI with and without BAV.
Methods: We retrospectively evaluated all TAVIs performed for predominant aortic
stenosis using the balloon-expandable Edwards Sapien XT and Sapien 3 devices
from March 2012 to April 2014. BAV was routinely performed only until May 2013.
We assessed Valve Academic Research Consortium (VARC)-2 deﬁned device suc-
cess and safety; differences in procedure and ﬂuoroscopy times and differences in
embolic load based on transcranial Doppler (TCD). Categorical variables were
analyzed using the Fisher exact test and continuous variables by the unpaired T-test
on SPSS v21.
Results: 61 patients underwent BAV (Group 1) and 52 patients had no BAV (Group
2). There was no difference (p>0.05) in the rate of device success, speciﬁcally
successful valve deployment (98.3% in Group 1 and 96.1% in Group 2), rate of
post-deployment balloon dilatation (3.4% in Group 1 and 4.0% in Group 2) or
incidence of moderate or severe aortic regurgitation (4.9% in Group 1 and 5.8% in
Group 2). There were no differences in procedure safety (50.8% VARC-2 deﬁned
major and minor complications in Group 1 and 34.6% in Group 2, p¼0.15). In one
case there was difﬁculty in crossing the valve without BAV, partial inﬂation of the
distal balloon tip within the TAVI valve enabled crossing of the native aortic valve
without subsequent deployment problems. There was a reduction in total ﬂuoro-
scopic time in Group 2 vs Group 1 (13.2 vs 17.3 mins, p¼0.006), but no signiﬁcant
difference in total procedure time (112 vs 119 mins, p¼0.21).There were no dif-
ferences between the 2 groups in terms of number of solid, gaseous or total emboli
on TCD (all p>0.05).
Conclusions: Balloon-expandable TAVI valves can be implanted transfemorally
without BAV, without a reduction in VARC-2 deﬁned success or safety. Without
performing a BAV there is a signiﬁcant reduction in the ﬂuoroscopic time. There is no
difference in the rate of embolization on TCD.
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Background: Transcatheter aortic valve implantation (TAVI) is the new standard of
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